Strategic Partnerships IDEAYA has active high-profile collaborations with Roche and AstraZeneca, targeting MTAP-deleted, RAS-mutant cancers and SCLC, plus immunotherapy combo studies. This signals open doors for co-development, licensing, and companion diagnostic opportunities that BD teams can leverage to structure milestone-driven deals and data-sharing arrangements.

Pipeline Milestones Pipeline milestones create multiple partnership entry points across stages, including IDE892 in early trials and darovasertib plus crizotinib in a registrational program for uveal melanoma, enabling potential co-development, strategic investments, and milestone-driven collaborations.

Biomarker Focus A strong emphasis on precision medicine and molecular diagnostics, including MTAP-deleted and RAS-mutant cancer contexts, creates opportunities to offer companion diagnostic development, biomarker services, and assay collaborations with pharma seeking biomarker-driven patient selection.

Growth Readiness A well-funded company with a track record of growth and a sizable employee base suggests readiness for joint ventures, strategic equity investments, or milestone-based collaborations with pharma partners.

Strategic Positioning Headquartered in the San Francisco Bay Area with leadership updates, IDEAYA is positioned to engage global pharma partners, accelerate clinical collaborations, and scale operations; approach BD with senior leadership alignment and a clear co-development roadmap.